AMRX
Amneal Pharmaceuticals Inc. Class A
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| 02-27-2019 | 02-27-2019 | 02-27-2019 | 02-27-2019 | 02-27-2019 | 02-27-2019 | 02-27-2019 | 02-27-2019 | 02-27-2019 | 02-27-2019 | 02-27-2019 | 02-27-2019 | 02-27-2019 | 02-27-2019 | 02-27-2019 | 11-07-2018 | 08-09-2018 | 03-01-2018 | 11-09-2017 | 08-09-2017 | 05-10-2017 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actual EPS | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.26 | 0.24 | 0.11 | 0.23 | 0.18 | 0.11 |
| Consensus EPS | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.25 | 0.23 | 0.12 | 0.19 | 0.14 | 0.12 |
| Estimated EPS | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 | 0.25 | 0.23 | 0.12 | 0.19 | 0.14 | 0.12 |
| Number of Estimates | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 7 | 8 | 6 | 7 | 6 | 6 |
| EPS Surprise | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | $0.01 | $0.01 | -$0.01 | $0.04 | $0.04 | -$0.01 |
Stats
Summary
Sector:
Industry:
Short Interest ():
Ethical Flags
Longest drawdown: 203 trading days
From: 2018-08-20 To: 2019-06-12
Lowest Point:
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2019 Update
via: SeekingAlpha at 2019-06-12 01:06:09:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Ole Andreas Halvorsen… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2019 Update
via: SeekingAlpha at 2019-06-12 01:06:09:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Ole Andreas Halvorsen… read more...
Amneal Pharmaceuticals to Present at Upcoming Investor Conferences
via: Business Wire at 2019-06-06 04:35:00:000
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will participate at the following upcoming investor conferences: Goldman Sachs 40 th Annual Global Healthcare Conference at 2:00 p.m. PT (5:00 p.m. ET) on June 12, 2019 in Rancho Palos Verdes, CA. … read more...
Amneal Pharmaceuticals to Present at Upcoming Investor Conferences
via: Business Wire at 2019-06-06 04:35:00:000
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will participate at the following upcoming investor conferences: Goldman Sachs 40 th Annual Global Healthcare Conference at 2:00 p.m. PT (5:00 p.m. ET) on June 12, 2019 in Rancho Palos Verdes, CA. … read more...
Amneal Pharmaceuticals to Present at Upcoming Investor Conferences
via: Business Wire at 2019-06-06 04:35:00:000
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will participate at the following upcoming investor conferences: Goldman Sachs 40 th Annual Global Healthcare Conference at 2:00 p.m. PT (5:00 p.m. ET) on June 12, 2019 in Rancho Palos Verdes, CA. … read more...
FCEL, STM among premarket gainers
via: SeekingAlpha at 2019-05-21 05:23:31:000
CIRCOR (NYSE: CIR ) +51% on Crane buyout offer . More news on: CIRCOR International, Inc., JMU Limited, Biocept, Inc., Stocks on the move, Read more … read more...
FCEL, STM among premarket gainers
via: SeekingAlpha at 2019-05-21 05:23:31:000
CIRCOR (NYSE: CIR ) +51% on Crane buyout offer . More news on: CIRCOR International, Inc., JMU Limited, Biocept, Inc., Stocks on the move, Read more … read more...
FCEL, STM among premarket gainers
via: SeekingAlpha at 2019-05-21 05:23:31:000
CIRCOR (NYSE: CIR ) +51% on Crane buyout offer . More news on: CIRCOR International, Inc., JMU Limited, Biocept, Inc., Stocks on the move, Read more … read more...
AMNEAL INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX
via: Business Wire at 2019-05-17 18:50:00:000
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF has commenced an investigation into Amneal Pharmaceuticals, Inc. (NYSE: AMRX). For many years, the Company, (formerly Impax … read more...
AMNEAL INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX
via: Business Wire at 2019-05-17 18:50:00:000
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF has commenced an investigation into Amneal Pharmaceuticals, Inc. (NYSE: AMRX). For many years, the Company, (formerly Impax … read more...
AMNEAL INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX
via: Business Wire at 2019-05-17 18:50:00:000
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF has commenced an investigation into Amneal Pharmaceuticals, Inc. (NYSE: AMRX). For many years, the Company, (formerly Impax … read more...
Gilead chief defends hefty Truvada price at government hearing
via: SeekingAlpha at 2019-05-17 07:34:43:000
Endpoints News reports that Gilead Sciences ( GILD +1.6% ) CEO Daniel O'Day spent more than three hours yesterday trying to justify the $2,000/month price of Truvada (emtricitabine and tenofovir disoproxil fumarate) before a U.S. House committee on oversight and reform. The FDA approved … read more...
Amneal Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference
via: Business Wire at 2019-05-15 05:25:00:000
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) today announced that members of management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 21, 2019 at 11:00 a.m. Eastern Time. To access a live webcast of the presentation, v… read more...
Amneal Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference
via: Business Wire at 2019-05-15 05:25:00:000
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) today announced that members of management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 21, 2019 at 11:00 a.m. Eastern Time. To access a live webcast of the presentation, v… read more...
AMNEAL INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Amneal Pharmaceuticals, Inc. To Contact The Firm
via: PR Newswire at 2019-05-13 13:49:00:000
NEW YORK , May 13, 2019 /PRNewswire/ --Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NYSE:AMRX). If you invested in Amneal stock or options and would li… read more...
AMNEAL INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Amneal Pharmaceuticals, Inc. To Contact The Firm
via: PR Newswire at 2019-05-13 13:49:00:000
NEW YORK , May 13, 2019 /PRNewswire/ --Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NYSE:AMRX). If you invested in Amneal stock or options and would li… read more...
Amneal Pharmaceuticals' (AMRX) CEO Rob Stewart on Q1 2019 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-05-09 10:56:27:000
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2019 Earnings Conference Call May 09, 2019 8:30 AM ET Company Participants Mark Donohue Vice President of Investor Relations and Corporate Communications Rob Stewart President and Chief Executive Officer Todd Branning  … read more...
Amneal Pharmaceuticals' (AMRX) CEO Rob Stewart on Q1 2019 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-05-09 10:56:27:000
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2019 Earnings Conference Call May 09, 2019 8:30 AM ET Company Participants Mark Donohue Vice President of Investor Relations and Corporate Communications Rob Stewart President and Chief Executive Officer Todd Branning  … read more...
Amneal Pharmaceuticals' (AMRX) CEO Rob Stewart on Q1 2019 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-05-09 10:56:27:000
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2019 Earnings Conference Call May 09, 2019 8:30 AM ET Company Participants Mark Donohue Vice President of Investor Relations and Corporate Communications Rob Stewart President and Chief Executive Officer Todd Branning  … read more...
Amneal Pharma down 16% on Q1 results
via: SeekingAlpha at 2019-05-09 06:20:15:000
Amneal Pharmaceuticals ( AMRX -16.1% ) Q1 results : Revenues: $446.1M (+62.1%). More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...
Amneal Pharma down 16% on Q1 results
via: SeekingAlpha at 2019-05-09 06:20:15:000
Amneal Pharmaceuticals ( AMRX -16.1% ) Q1 results : Revenues: $446.1M (+62.1%). More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...
Amneal Pharma down 16% on Q1 results
via: SeekingAlpha at 2019-05-09 06:20:15:000
Amneal Pharmaceuticals ( AMRX -16.1% ) Q1 results : Revenues: $446.1M (+62.1%). More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...
Amneal Pharmaceuticals, Inc. 2019 Q1 - Results - Earnings Call Slides
via: SeekingAlpha at 2019-05-09 06:19:14:000
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2019 Q1 earnings Read more … read more...
Amneal Pharmaceuticals, Inc. 2019 Q1 - Results - Earnings Call Slides
via: SeekingAlpha at 2019-05-09 06:19:14:000
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2019 Q1 earnings Read more … read more...
Amneal Pharmaceuticals, Inc. 2019 Q1 - Results - Earnings Call Slides
via: SeekingAlpha at 2019-05-09 06:19:14:000
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2019 Q1 earnings Read more … read more...
Amneal Pharmaceuticals misses by $0.04, beats on revenue
via: SeekingAlpha at 2019-05-09 02:34:37:000
Amneal Pharmaceuticals (NYSE: AMRX ): Q1 Non-GAAP EPS of $0.14 misses by $0.04 ; GAAP EPS of -$0.37. More news on: Amneal Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Amneal Pharmaceuticals misses by $0.04, beats on revenue
via: SeekingAlpha at 2019-05-09 02:34:37:000
Amneal Pharmaceuticals (NYSE: AMRX ): Q1 Non-GAAP EPS of $0.14 misses by $0.04 ; GAAP EPS of -$0.37. More news on: Amneal Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Amneal Pharmaceuticals misses by $0.04, beats on revenue
via: SeekingAlpha at 2019-05-09 02:34:37:000
Amneal Pharmaceuticals (NYSE: AMRX ): Q1 Non-GAAP EPS of $0.14 misses by $0.04 ; GAAP EPS of -$0.37. More news on: Amneal Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Amneal Reports First Quarter 2019 Financial Results
via: Business Wire at 2019-05-09 02:30:00:000
Q1 2019 Net Revenue of $446 Million; GAAP Loss per share of $0.37; Combined Adjusted Diluted EPS (1) of $0.14 Continued Progress in Diversifying Portfolio and Optimizing Business Reaffirming Full Year 2019 Financial Guidance  … read more...
Amneal Reports First Quarter 2019 Financial Results
via: Business Wire at 2019-05-09 02:30:00:000
Q1 2019 Net Revenue of $446 Million; GAAP Loss per share of $0.37; Combined Adjusted Diluted EPS (1) of $0.14 Continued Progress in Diversifying Portfolio and Optimizing Business Reaffirming Full Year 2019 Financial Guidance  … read more...
Amneal Reports First Quarter 2019 Financial Results
via: Business Wire at 2019-05-09 02:30:00:000
Q1 2019 Net Revenue of $446 Million; GAAP Loss per share of $0.37; Combined Adjusted Diluted EPS (1) of $0.14 Continued Progress in Diversifying Portfolio and Optimizing Business Reaffirming Full Year 2019 Financial Guidance  … read more...
Amneal to Report First Quarter 2019 Results on May 9, 2019
via: Business Wire at 2019-04-08 04:05:00:000
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its first quarter 2019 financial results on Thursday, May 9, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on Ma… read more...
Amneal to Report First Quarter 2019 Results on May 9, 2019
via: Business Wire at 2019-04-08 04:05:00:000
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its first quarter 2019 financial results on Thursday, May 9, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on Ma… read more...
Amneal to Report First Quarter 2019 Results on May 9, 2019
via: Business Wire at 2019-04-08 04:05:00:000
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its first quarter 2019 financial results on Thursday, May 9, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on Ma… read more...
Amneal Names Pradeep Bhadauria as Chief Scientific Officer
via: Business Wire at 2019-04-02 03:00:00:000
Skilled R&D leader brings more than two decades of generic and specialty experience Led development of more than 200 products, including numerous first-to-file and first-to-market opportunities - Expertise in developing complex and difficult-to-formulate generics … read more...
Amneal Names Pradeep Bhadauria as Chief Scientific Officer
via: Business Wire at 2019-04-02 03:00:00:000
Skilled R&D leader brings more than two decades of generic and specialty experience Led development of more than 200 products, including numerous first-to-file and first-to-market opportunities - Expertise in developing complex and difficult-to-formulate generics … read more...
Amneal Names Pradeep Bhadauria as Chief Scientific Officer
via: Business Wire at 2019-04-02 03:00:00:000
Skilled R&D leader brings more than two decades of generic and specialty experience Led development of more than 200 products, including numerous first-to-file and first-to-market opportunities - Expertise in developing complex and difficult-to-formulate generics … read more...
Amneal Announces Agreement with Zentiva to Divest Creo Pharma
via: PR Newswire at 2019-04-01 04:31:00:000
BRIDGEWATER, N.J. , April 1, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has entered into an agreement with Zentiva Group a.s., under which Zentiva has acquired Creo Pharmaceuticals Ltd., a subsidiary of Amneal that operates the co… read more...
Impax Labs pay-for-delay deal for generic Opana ER illegal - FTC
via: SeekingAlpha at 2019-04-01 03:33:30:000
In a unanimous vote, the U.S. Federal Trade Commission (FTC) rules that Impax Laboratories LLC (NYSE: AMRX ) entered into an illegal pay-for-delay scheme with Endo Pharmaceuticals (NASDAQ: ENDP ) aimed at keeping the former's generic version of opioid pain med Opana ER (oxymorphone hydroch… read more...
Daily Insider Ratings Round Up 3/12/19
via: SeekingAlpha at 2019-03-14 07:00:14:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 3/12/19
via: SeekingAlpha at 2019-03-14 07:00:14:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Daily Insider Ratings Round Up 3/12/19
via: SeekingAlpha at 2019-03-14 07:00:14:000
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...
Amneal Announces Launch of Rivastigmine Transdermal System
via: PR Newswire at 2019-03-12 04:30:00:000
BRIDGEWATER, N.J. , March 12, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has launched its generic version of Exelon Patch (Rivastigmine Transdermal System), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. The Compa… read more...
Amneal Announces Launch of Rivastigmine Transdermal System
via: PR Newswire at 2019-03-12 04:30:00:000
BRIDGEWATER, N.J. , March 12, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has launched its generic version of Exelon Patch (Rivastigmine Transdermal System), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. The Compa… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2018 Update
via: SeekingAlpha at 2019-03-11 00:09:52:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 02/14/2019. Please visit our Tracking Ole Andreas Halvorsen&#… read more...
Amneal Pharmaceuticals to Present at the Barclays Global Healthcare Conference
via: PR Newswire at 2019-03-06 03:35:00:000
BRIDGEWATER, N.J. , March 6, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will participate in a fireside chat at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel in Miami on Wednesday, March 13, 2019 …. read more...
Amneal Pharmaceuticals to Present at the Barclays Global Healthcare Conference
via: PR Newswire at 2019-03-06 03:35:00:000
BRIDGEWATER, N.J. , March 6, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will participate in a fireside chat at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel in Miami on Wednesday, March 13, 2019 …. read more...
Amneal Pharmaceuticals to Present at the Barclays Global Healthcare Conference
via: PR Newswire at 2019-03-06 03:35:00:000
BRIDGEWATER, N.J. , March 6, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will participate in a fireside chat at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel in Miami on Wednesday, March 13, 2019 …. read more...
Amneal Pharmaceuticals, Inc (AMRX) CEO Rob Stewart on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-02-28 14:04:06:000
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2018 Results Earnings Conference Call February 28, 2019, 08:30 AM ET Company Participants Mark Donohue - Vice President, Investor Relations and Corporate Communications Rob Stewart - President and Chief Executive Officer Todd Branning - Chie… read more...
Amneal Pharmaceuticals, Inc. 2018 Q4 - Results - Earnings Call Slides
via: SeekingAlpha at 2019-02-28 09:25:44:000
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2018 Q4 earnings Read more … read more...
Amneal Pharmaceuticals, Inc (AMRX) CEO Rob Stewart on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-02-28 09:04:06:000
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2018 Results Earnings Conference Call February 28, 2019, 08:30 AM ET Company Participants Mark Donohue - Vice President, Investor Relations and Corporate Communications Rob Stewart - President and Chief Executive Officer Todd Branning - Chie… read more...
Amneal Pharmaceuticals, Inc (AMRX) CEO Rob Stewart on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-02-28 09:04:06:000
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2018 Results Earnings Conference Call February 28, 2019, 08:30 AM ET Company Participants Mark Donohue - Vice President, Investor Relations and Corporate Communications Rob Stewart - President and Chief Executive Officer Todd Branning - Chie… read more...
Amneal Pharmaceuticals beats by $0.06, beats on revenue
via: SeekingAlpha at 2019-02-28 07:33:26:000
Amneal Pharmaceuticals (NYSE: AMRX ): Q4 Non-GAAP EPS of $0.33 beats by $0.06 ; GAAP EPS of -$0.07 misses by $0.32 . More news on: Amneal Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Amneal Reports Fourth Quarter And Full Year 2018 Financial Results
via: PR Newswire at 2019-02-28 07:30:00:000
BRIDGEWATER, N.J. , Feb. 28, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the fourth quarter and year ended December 31, 2018 . Executive Commentary "We ended a year o… read more...
Amneal Pharmaceuticals, Inc. 2018 Q4 - Results - Earnings Call Slides
via: SeekingAlpha at 2019-02-28 04:25:44:000
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2018 Q4 earnings Read more … read more...
Amneal Pharmaceuticals, Inc. 2018 Q4 - Results - Earnings Call Slides
via: SeekingAlpha at 2019-02-28 04:25:44:000
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2018 Q4 earnings Read more … read more...
Amneal Pharmaceuticals beats by $0.06, beats on revenue
via: SeekingAlpha at 2019-02-28 02:33:26:000
Amneal Pharmaceuticals (NYSE: AMRX ): Q4 Non-GAAP EPS of $0.33 beats by $0.06 ; GAAP EPS of -$0.07 misses by $0.32 . More news on: Amneal Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Amneal Pharmaceuticals beats by $0.06, beats on revenue
via: SeekingAlpha at 2019-02-28 02:33:26:000
Amneal Pharmaceuticals (NYSE: AMRX ): Q4 Non-GAAP EPS of $0.33 beats by $0.06 ; GAAP EPS of -$0.07 misses by $0.32 . More news on: Amneal Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Amneal Reports Fourth Quarter And Full Year 2018 Financial Results
via: PR Newswire at 2019-02-28 02:30:00:000
BRIDGEWATER, N.J. , Feb. 28, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the fourth quarter and year ended December 31, 2018 . Executive Commentary "We ended a year o… read more...
Amneal Reports Fourth Quarter And Full Year 2018 Financial Results
via: PR Newswire at 2019-02-28 02:30:00:000
BRIDGEWATER, N.J. , Feb. 28, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the fourth quarter and year ended December 31, 2018 . Executive Commentary "We ended a year o… read more...
Notable earnings before Thursday's open
via: SeekingAlpha at 2019-02-27 17:30:45:000
AAON , ABB , ACIW , AKRX , AMCX , AMRX , BCPC , BID , BMCH , BPMP , BUD , CARS , CM , CMD , CNP , CROX , CWEN , CWT , DAVA , DEA , EGRX , ENDP , EXLS , FOLD , FRO , FSS , GOLF , GTN , GTT , HMHC , HRI , IBP , ICPT , IRDM , JCP , JD , KDP , LAUR , LKQ ,… read more...
Amneal to Report Fourth Quarter and Full Year 2018 Results on February 28, 2019
via: PR Newswire at 2019-01-24 07:30:00:000
BRIDGEWATER, N.J. , Jan. 24, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2018 financial results on Thursday, February 28, 2019 , prior to the open of the U.S. financial markets. … read more...
Amneal to Report Fourth Quarter and Full Year 2018 Results on February 28, 2019
via: PR Newswire at 2019-01-24 07:30:00:000
BRIDGEWATER, N.J. , Jan. 24, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2018 financial results on Thursday, February 28, 2019 , prior to the open of the U.S. financial markets. … read more...
Amneal to Report Fourth Quarter and Full Year 2018 Results on February 28, 2019
via: PR Newswire at 2019-01-24 07:30:00:000
BRIDGEWATER, N.J. , Jan. 24, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2018 financial results on Thursday, February 28, 2019 , prior to the open of the U.S. financial markets. … read more...
Amneal Names Accomplished Finance Executive Todd P. Branning As Chief Financial Officer
via: PR Newswire at 2019-01-22 06:55:00:000
BRIDGEWATER, N.J. , Jan. 22, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it has appointed Todd P. Branning as Senior Vice President and Chief Financial Officer, effective today. Mr. Branning will be responsible for leading Amneal's glo… read more...
Amneal Names Accomplished Finance Executive Todd P. Branning As Chief Financial Officer
via: PR Newswire at 2019-01-22 06:55:00:000
BRIDGEWATER, N.J. , Jan. 22, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it has appointed Todd P. Branning as Senior Vice President and Chief Financial Officer, effective today. Mr. Branning will be responsible for leading Amneal's glo… read more...
Amneal Announces Approval of Rivastigmine Transdermal System
via: PR Newswire at 2019-01-14 07:30:00:000
BRIDGEWATER, N.J. , Jan. 14, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of Exelon Patch (Rivastigmine Transdermal System), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg… read more...
Amneal Announces Approval of Rivastigmine Transdermal System
via: PR Newswire at 2019-01-14 07:30:00:000
BRIDGEWATER, N.J. , Jan. 14, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of Exelon Patch (Rivastigmine Transdermal System), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg… read more...
Amneal Announces Approval of Rivastigmine Transdermal System
via: PR Newswire at 2019-01-14 07:30:00:000
BRIDGEWATER, N.J. , Jan. 14, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of Exelon Patch (Rivastigmine Transdermal System), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg… read more...
Amneal Pharmaceuticals (AMRX) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
via: SeekingAlpha at 2019-01-08 13:26:00:000
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Amneal Pharmaceuticals (AMRX) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
via: SeekingAlpha at 2019-01-08 13:26:00:000
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Amneal Pharmaceuticals (AMRX) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
via: SeekingAlpha at 2019-01-08 13:26:00:000
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Teva outlook on stable prices buoys generics
via: SeekingAlpha at 2019-01-07 15:51:50:000
Generic drug makers are in the green after Teva Pharmaceutical Industries ( TEVA +1.9% ) chief Kre Schultz stated that he sees stable prices this year, a welcome view considering the downward pressure last year. He made the comment during his presentation at the JP Morgan Healthcare … read more...
Amneal Names David A. Buchen Senior Vice President, Chief Legal Officer And Corporate Secretary
via: PR Newswire at 2019-01-04 07:30:00:000
BRIDGEWATER, N.J. , Jan. 4, 2019 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that it has appointed David A. Buchen to the newly expanded role of Senior Vice President, Chief Legal Officer and Corporate Secretary, reporting to President and Chief Exec… read more...
Amneal Names David A. Buchen Senior Vice President, Chief Legal Officer And Corporate Secretary
via: PR Newswire at 2019-01-04 07:30:00:000
BRIDGEWATER, N.J. , Jan. 4, 2019 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that it has appointed David A. Buchen to the newly expanded role of Senior Vice President, Chief Legal Officer and Corporate Secretary, reporting to President and Chief Exec… read more...
Amneal Names David A. Buchen Senior Vice President, Chief Legal Officer And Corporate Secretary
via: PR Newswire at 2019-01-04 07:30:00:000
BRIDGEWATER, N.J. , Jan. 4, 2019 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that it has appointed David A. Buchen to the newly expanded role of Senior Vice President, Chief Legal Officer and Corporate Secretary, reporting to President and Chief Exec… read more...
Amneal Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
via: PR Newswire at 2018-12-19 08:35:00:000
BRIDGEWATER, N.J. , Dec. 19, 2018 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will present at the 37 th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco on Tuesday, January 8, 2019 . Ro… read more...
Amneal Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
via: PR Newswire at 2018-12-19 08:35:00:000
BRIDGEWATER, N.J. , Dec. 19, 2018 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will present at the 37 th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco on Tuesday, January 8, 2019 . Ro… read more...
Amneal Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
via: PR Newswire at 2018-12-19 08:35:00:000
BRIDGEWATER, N.J. , Dec. 19, 2018 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will present at the 37 th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco on Tuesday, January 8, 2019 . Ro… read more...
Goldman bearish on Walgreens Boots Alliance in premarket analyst action; shares down 4% premarket
via: SeekingAlpha at 2018-12-14 08:48:20:000
Amedisys (NASDAQ: AMED ) initiated with Equal Weight rating and $130 (flat) price target at Barclays. More news on: AMEDISYS Inc, American Renal Associates Holdings, DaVita HealthCare Partners Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Goldman bearish on Walgreens Boots Alliance in premarket analyst action; shares down 4% premarket
via: SeekingAlpha at 2018-12-14 08:48:20:000
Amedisys (NASDAQ: AMED ) initiated with Equal Weight rating and $130 (flat) price target at Barclays. More news on: AMEDISYS Inc, American Renal Associates Holdings, DaVita HealthCare Partners Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Goldman bearish on Walgreens Boots Alliance in premarket analyst action; shares down 4% premarket
via: SeekingAlpha at 2018-12-14 08:48:20:000
Amedisys (NASDAQ: AMED ) initiated with Equal Weight rating and $130 (flat) price target at Barclays. More news on: AMEDISYS Inc, American Renal Associates Holdings, DaVita HealthCare Partners Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Goldman bearish on Walgreens Boots Alliance in premarket analyst action; shares down 4% premarket
via: SeekingAlpha at 2018-12-14 08:48:20:000
Amedisys (NASDAQ: AMED ) initiated with Equal Weight rating and $130 (flat) price target at Barclays. More news on: AMEDISYS Inc, American Renal Associates Holdings, DaVita HealthCare Partners Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Goldman bearish on Walgreens Boots Alliance in premarket analyst action; shares down 4% premarket
via: SeekingAlpha at 2018-12-14 08:48:20:000
Amedisys (NASDAQ: AMED ) initiated with Equal Weight rating and $130 (flat) price target at Barclays. More news on: AMEDISYS Inc, American Renal Associates Holdings, DaVita HealthCare Partners Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Generics under pressure on expanded price-fixing investigation
via: SeekingAlpha at 2018-12-10 12:53:46:000
The broad market's bearishness notwithstanding, generic drug makers are predominantly in the red on the news that the investigation into alleged price-fixing by state AGs now totals 47. More news on: Aceto Corporation, Aclaris Therapeutics, Akorn, Inc., Healthcare stocks news, Stocks on th… read more...
Generics under pressure on expanded price-fixing investigation
via: SeekingAlpha at 2018-12-10 12:53:46:000
The broad market's bearishness notwithstanding, generic drug makers are predominantly in the red on the news that the investigation into alleged price-fixing by state AGs now totals 47. More news on: Aceto Corporation, Aclaris Therapeutics, Akorn, Inc., Healthcare stocks news, Stocks on th… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2018 Update
via: SeekingAlpha at 2018-11-26 10:05:28:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 11/14/2018. Please visit our Tracking Ole Andreas Halvorsen… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2018 Update
via: SeekingAlpha at 2018-11-26 10:05:28:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 11/14/2018. Please visit our Tracking Ole Andreas Halvorsen… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2018 Update
via: SeekingAlpha at 2018-11-26 10:05:28:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 11/14/2018. Please visit our Tracking Ole Andreas Halvorsen… read more...
Johnson & Johnson -3% following negative appeals court ruling on Zytiga
via: SeekingAlpha at 2018-11-21 14:10:04:000
Johnson & Johnson ( JNJ -3.3% ) is today's biggest decliner on the Dow after hitting all-time highs yesterday, after a U.S. appeals court rules JNJ cannot prevent sales of generic Zytiga while the company appeals a trial judge's ruling that invalidated a patent on the prostate cancer… read more...
Johnson & Johnson -3% following negative appeals court ruling on Zytiga
via: SeekingAlpha at 2018-11-21 14:10:04:000
Johnson & Johnson ( JNJ -3.3% ) is today's biggest decliner on the Dow after hitting all-time highs yesterday, after a U.S. appeals court rules JNJ cannot prevent sales of generic Zytiga while the company appeals a trial judge's ruling that invalidated a patent on the prostate cancer… read more...
Johnson & Johnson -3% following negative appeals court ruling on Zytiga
via: SeekingAlpha at 2018-11-21 14:10:04:000
Johnson & Johnson ( JNJ -3.3% ) is today's biggest decliner on the Dow after hitting all-time highs yesterday, after a U.S. appeals court rules JNJ cannot prevent sales of generic Zytiga while the company appeals a trial judge's ruling that invalidated a patent on the prostate cancer… read more...
Johnson & Johnson -3% following negative appeals court ruling on Zytiga
via: SeekingAlpha at 2018-11-21 14:10:04:000
Johnson & Johnson ( JNJ -3.3% ) is today's biggest decliner on the Dow after hitting all-time highs yesterday, after a U.S. appeals court rules JNJ cannot prevent sales of generic Zytiga while the company appeals a trial judge's ruling that invalidated a patent on the prostate cancer… read more...
Amneal to Present at the 30th Annual Piper Jaffray Healthcare Conference
via: PR Newswire at 2018-11-21 08:35:00:000
BRIDGEWATER, N.J. , Nov. 21, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it will present at the Piper Jaffray Healthcare Conference in New York, NY , on Tuesday, November 27, 2018 at 1:00 p.m. ET . To access a live webcast of t… read more...
Amneal to Present at the 30th Annual Piper Jaffray Healthcare Conference
via: PR Newswire at 2018-11-21 08:35:00:000
BRIDGEWATER, N.J. , Nov. 21, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it will present at the Piper Jaffray Healthcare Conference in New York, NY , on Tuesday, November 27, 2018 at 1:00 p.m. ET . To access a live webcast of t… read more...
Amneal to Present at the 30th Annual Piper Jaffray Healthcare Conference
via: PR Newswire at 2018-11-21 08:35:00:000
BRIDGEWATER, N.J. , Nov. 21, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it will present at the Piper Jaffray Healthcare Conference in New York, NY , on Tuesday, November 27, 2018 at 1:00 p.m. ET . To access a live webcast of t… read more...
Amneal to Present at the 30th Annual Piper Jaffray Healthcare Conference
via: PR Newswire at 2018-11-21 08:35:00:000
BRIDGEWATER, N.J. , Nov. 21, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it will present at the Piper Jaffray Healthcare Conference in New York, NY , on Tuesday, November 27, 2018 at 1:00 p.m. ET . To access a live webcast of t… read more...
Amneal Completes Transition Agreement With Lannett Company To Begin Commercialization Of Levothyroxine On December 1st
via: PR Newswire at 2018-11-12 06:55:00:000
BRIDGEWATER, N.J. , Nov. 12, 2018 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it has completed a transition agreement with Lannett Company. Under the terms of the agreement, Amneal will take over the distribution and marketing of Levothyroxine sodiu… read more...
Amneal Completes Transition Agreement With Lannett Company To Begin Commercialization Of Levothyroxine On December 1st
via: PR Newswire at 2018-11-12 06:55:00:000
BRIDGEWATER, N.J. , Nov. 12, 2018 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it has completed a transition agreement with Lannett Company. Under the terms of the agreement, Amneal will take over the distribution and marketing of Levothyroxine sodiu… read more...
Amneal Completes Transition Agreement With Lannett Company To Begin Commercialization Of Levothyroxine On December 1st
via: PR Newswire at 2018-11-12 06:55:00:000
BRIDGEWATER, N.J. , Nov. 12, 2018 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it has completed a transition agreement with Lannett Company. Under the terms of the agreement, Amneal will take over the distribution and marketing of Levothyroxine sodiu… read more...
Amneal Pharmaceuticals' (AMRX) CEO Rob Stewart on Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-11-07 13:47:05:000
Amneal Pharmaceuticals Inc. (AMRX) Q3 2018 Earnings Conference Call November 7, 2018 8:30 AM ET Executives Mark Donohue Vice President, Investor Relations and Corporate Communications Rob Stewart President and Chief Executive Officer Bryan Reasons Chief… read more...
Amneal Pharmaceuticals' (AMRX) CEO Rob Stewart on Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-11-07 13:47:05:000
Amneal Pharmaceuticals Inc. (AMRX) Q3 2018 Earnings Conference Call November 7, 2018 8:30 AM ET Executives Mark Donohue Vice President, Investor Relations and Corporate Communications Rob Stewart President and Chief Executive Officer Bryan Reasons Chief… read more...
Amneal Pharmaceuticals' (AMRX) CEO Rob Stewart on Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-11-07 13:47:05:000
Amneal Pharmaceuticals Inc. (AMRX) Q3 2018 Earnings Conference Call November 7, 2018 8:30 AM ET Executives Mark Donohue Vice President, Investor Relations and Corporate Communications Rob Stewart President and Chief Executive Officer Bryan Reasons Chief… read more...
Amneal Pharmaceuticals, Inc. 2018 Q3 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-11-07 10:16:23:000
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2018 Q3 earnings Read more … read more...
Amneal Pharmaceuticals, Inc. 2018 Q3 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-11-07 10:16:23:000
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2018 Q3 earnings Read more … read more...
Amneal Pharmaceuticals, Inc. 2018 Q3 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-11-07 10:16:23:000
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2018 Q3 earnings Read more … read more...
Amneal Pharmaceuticals reports Q3 results
via: SeekingAlpha at 2018-11-07 06:57:56:000
Amneal Pharmaceuticals (NYSE: AMRX ): Q3 Non-GAAP EPS of $0.28; GAAP EPS of $0.05. More news on: Amneal Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Amneal Pharmaceuticals reports Q3 results
via: SeekingAlpha at 2018-11-07 06:57:56:000
Amneal Pharmaceuticals (NYSE: AMRX ): Q3 Non-GAAP EPS of $0.28; GAAP EPS of $0.05. More news on: Amneal Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Amneal Pharmaceuticals reports Q3 results
via: SeekingAlpha at 2018-11-07 06:57:56:000
Amneal Pharmaceuticals (NYSE: AMRX ): Q3 Non-GAAP EPS of $0.28; GAAP EPS of $0.05. More news on: Amneal Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Amneal Announces Solid Third Quarter 2018 Financial Results
via: PR Newswire at 2018-11-07 06:55:00:000
BRIDGEWATER, N.J. , Nov. 7, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the quarter ended September 30, 2018 . "The third quarter was defined by solid financial performance and strategic accomplishments as we a… read more...
Amneal Announces Solid Third Quarter 2018 Financial Results
via: PR Newswire at 2018-11-07 06:55:00:000
BRIDGEWATER, N.J. , Nov. 7, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the quarter ended September 30, 2018 . "The third quarter was defined by solid financial performance and strategic accomplishments as we a… read more...
Amneal Announces Solid Third Quarter 2018 Financial Results
via: PR Newswire at 2018-11-07 06:55:00:000
BRIDGEWATER, N.J. , Nov. 7, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the quarter ended September 30, 2018 . "The third quarter was defined by solid financial performance and strategic accomplishments as we a… read more...
Notable earnings before Wednesday's open
via: SeekingAlpha at 2018-11-06 17:30:01:000
ALNY , AMRX , ANDX , ASC , AVA , CARS , CDK , CLNY , CNDT , CNHI , COTY , CRL , CSTE , DF , DISH , DLPH , ENBL , FOXA , GEO , GIB , GRPN , HUM , HZNP , KELYA , KORS , MDP , MGLN , MIDD , MNTA , NSIT , ODP , PFGC , RCM , RDWR , ROK , SBGI , SMG , SMI , … read more...
Expiration Dates for Certain Lots of Generic Adrenaclick® Epinephrine Injection, USP Auto-Injector Extended to 20 Months
via: PR Newswire at 2018-10-25 10:00:00:000
BRIDGEWATER, N.J. , Oct. 25, 2018 /PRNewswire/ -- Impax Laboratories LLC (the "Company"), a subsidiary of Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that in collaboration with the U.S. Food and Drug Administration (FDA), the Company is extending the expiration dates for … read more...
Expiration Dates for Certain Lots of Generic Adrenaclick® Epinephrine Injection, USP Auto-Injector Extended to 20 Months
via: PR Newswire at 2018-10-25 10:00:00:000
BRIDGEWATER, N.J. , Oct. 25, 2018 /PRNewswire/ -- Impax Laboratories LLC (the "Company"), a subsidiary of Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that in collaboration with the U.S. Food and Drug Administration (FDA), the Company is extending the expiration dates for … read more...
Expiration Dates for Certain Lots of Generic Adrenaclick® Epinephrine Injection, USP Auto-Injector Extended to 20 Months
via: PR Newswire at 2018-10-25 10:00:00:000
BRIDGEWATER, N.J. , Oct. 25, 2018 /PRNewswire/ -- Impax Laboratories LLC (the "Company"), a subsidiary of Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that in collaboration with the U.S. Food and Drug Administration (FDA), the Company is extending the expiration dates for … read more...
Amneal Announces Issuance of New Patent for IPX203, an Investigational Extended-Release Formulation of Carbidopa-Levodopa
via: PR Newswire at 2018-10-24 07:30:00:000
BRIDGEWATER, N.J. , Oct. 24, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that a patent protectingIPX203has been issued by the United States Patent and Trademark Office. U.S. Patent No. 10,098,845 covers controlled releaseformula… read more...
Amneal Announces Approval and Launch of Clobazam Tablets and Clobazam Oral Suspension
via: PR Newswire at 2018-10-23 07:30:00:000
BRIDGEWATER, N.J. , Oct. 23, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of Onfi (clobazam) tablets, 10 mg and 20 mg for oral use, CIV, and Onfi (clobazam) oral suspensio… read more...
Amneal Announces Approval of Carmustine for Injection USP, 100 mg/vial - Preparing for Launch
via: PR Newswire at 2018-10-19 08:00:00:000
BRIDGEWATER, N.J. , Oct. 19, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of BiCNU (carmustine) for injection, 100 mg. The Company is planning to commercialize its Carmustine … read more...
Amneal Announces Approval of Carmustine for Injection USP, 100 mg/vial - Preparing for Launch
via: PR Newswire at 2018-10-19 08:00:00:000
BRIDGEWATER, N.J. , Oct. 19, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of BiCNU (carmustine) for injection, 100 mg. The Company is planning to commercialize its Carmustine … read more...
Amneal Announces Approval of Carmustine for Injection USP, 100 mg/vial - Preparing for Launch
via: PR Newswire at 2018-10-19 08:00:00:000
BRIDGEWATER, N.J. , Oct. 19, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of BiCNU (carmustine) for injection, 100 mg. The Company is planning to commercialize its Carmustine … read more...
Amneal Announces Approval of Carmustine for Injection USP, 100 mg/vial - Preparing for Launch
via: PR Newswire at 2018-10-19 08:00:00:000
BRIDGEWATER, N.J. , Oct. 19, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of BiCNU (carmustine) for injection, 100 mg. The Company is planning to commercialize its Carmustine … read more...
Amneal Announces the Approval and Launch of Generic Isoproterenol Hydrochloride Injection USP
via: PR Newswire at 2018-10-19 07:30:00:000
BRIDGEWATER, N.J. , Oct. 19, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of Isuprel TM Injection (isoproterenol hydrochloride) USP, 0.2 mg/mL and 1 mg/5 mL(0.2 mg/mL) Single-Dose Vials. The… read more...
Amneal Announces the Approval and Launch of Generic Isoproterenol Hydrochloride Injection USP
via: PR Newswire at 2018-10-19 07:30:00:000
BRIDGEWATER, N.J. , Oct. 19, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of Isuprel TM Injection (isoproterenol hydrochloride) USP, 0.2 mg/mL and 1 mg/5 mL(0.2 mg/mL) Single-Dose Vials. The… read more...
Amneal Announces the Approval and Launch of Generic Isoproterenol Hydrochloride Injection USP
via: PR Newswire at 2018-10-19 07:30:00:000
BRIDGEWATER, N.J. , Oct. 19, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of Isuprel TM Injection (isoproterenol hydrochloride) USP, 0.2 mg/mL and 1 mg/5 mL(0.2 mg/mL) Single-Dose Vials. The… read more...
Amneal Announces the Approval and Launch of Generic Isoproterenol Hydrochloride Injection USP
via: PR Newswire at 2018-10-19 07:30:00:000
BRIDGEWATER, N.J. , Oct. 19, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of Isuprel TM Injection (isoproterenol hydrochloride) USP, 0.2 mg/mL and 1 mg/5 mL(0.2 mg/mL) Single-Dose Vials. The… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-10-16 07:49:45:000
Abbott (NYSE: ABT ) initiated with Overweight rating and $80 (16% upside) price target at Barclays. More news on: Abbott Laboratories, Arbutus Biopharma Corp, Avanos Medical, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-10-16 07:49:45:000
Abbott (NYSE: ABT ) initiated with Overweight rating and $80 (16% upside) price target at Barclays. More news on: Abbott Laboratories, Arbutus Biopharma Corp, Avanos Medical, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-10-16 07:49:45:000
Abbott (NYSE: ABT ) initiated with Overweight rating and $80 (16% upside) price target at Barclays. More news on: Abbott Laboratories, Arbutus Biopharma Corp, Avanos Medical, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Generics in the green following proposed favorable guidance from FDA
via: SeekingAlpha at 2018-10-02 14:03:56:000
Most generic drug firms are enjoying an uptick in buying. This morning, FDA Commissioner Scott Gottlieb, M.D., released a statement on preliminary guidance aimed at making the review process for generic drug applications more efficient. More news on: Aceto Corporation, Aclaris Therapeutics… read more...
Generics in the green following proposed favorable guidance from FDA
via: SeekingAlpha at 2018-10-02 14:03:56:000
Most generic drug firms are enjoying an uptick in buying. This morning, FDA Commissioner Scott Gottlieb, M.D., released a statement on preliminary guidance aimed at making the review process for generic drug applications more efficient. More news on: Aceto Corporation, Aclaris Therapeutics… read more...
Generics in the green following proposed favorable guidance from FDA
via: SeekingAlpha at 2018-10-02 14:03:56:000
Most generic drug firms are enjoying an uptick in buying. This morning, FDA Commissioner Scott Gottlieb, M.D., released a statement on preliminary guidance aimed at making the review process for generic drug applications more efficient. More news on: Aceto Corporation, Aclaris Therapeutics… read more...
Amneal to Present at the Cantor Fitzgerald Global Healthcare Conference
via: PR Newswire at 2018-09-24 07:35:00:000
BRIDGEWATER, N.J. , Sept. 24, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it will present at the Cantor Fitzgerald Global Healthcare Conference in New York, NY , on Monday, October 1, 2018 at 2:55 p.m. ET . To access a live we… read more...
Amneal to Present at the Cantor Fitzgerald Global Healthcare Conference
via: PR Newswire at 2018-09-24 07:35:00:000
BRIDGEWATER, N.J. , Sept. 24, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it will present at the Cantor Fitzgerald Global Healthcare Conference in New York, NY , on Monday, October 1, 2018 at 2:55 p.m. ET . To access a live we… read more...
Amneal to Present at the Cantor Fitzgerald Global Healthcare Conference
via: PR Newswire at 2018-09-24 07:35:00:000
BRIDGEWATER, N.J. , Sept. 24, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it will present at the Cantor Fitzgerald Global Healthcare Conference in New York, NY , on Monday, October 1, 2018 at 2:55 p.m. ET . To access a live we… read more...
Amneal to Report Third Quarter 2018 Results on November 7, 2018
via: PR Newswire at 2018-09-21 08:30:00:000
BRIDGEWATER, N.J. , Sept. 21, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2018 financial results on Wednesday, November 7, 2018 , prior to the open of the U.S. financial markets. The Company will host a … read more...
Amneal to Report Third Quarter 2018 Results on November 7, 2018
via: PR Newswire at 2018-09-21 08:30:00:000
BRIDGEWATER, N.J. , Sept. 21, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2018 financial results on Wednesday, November 7, 2018 , prior to the open of the U.S. financial markets. The Company will host a … read more...
Amneal to Report Third Quarter 2018 Results on November 7, 2018
via: PR Newswire at 2018-09-21 08:30:00:000
BRIDGEWATER, N.J. , Sept. 21, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2018 financial results on Wednesday, November 7, 2018 , prior to the open of the U.S. financial markets. The Company will host a … read more...
Your Daily Pharma Scoop: FibroGen Fast Tracked, Dr. Reddy's Entry, Bristol-Myers Succeeds
via: SeekingAlpha at 2018-09-15 00:16:06:000
Stocks in News: [[FGEN]], [[RDY]] FibroGen's pamrevlumab fast tracked for IPF . Discussion : FibroGen's anti-CTGF antibody pamrevlumab indicated in idiopathic pulmonary fibrosis ((IPF)) is now under Fast Track review of the FDA. The new status allows a rolling review of the market… read more...
Your Daily Pharma Scoop: FibroGen Fast Tracked, Dr. Reddy's Entry, Bristol-Myers Succeeds
via: SeekingAlpha at 2018-09-15 00:16:06:000
Stocks in News: [[FGEN]], [[RDY]] FibroGen's pamrevlumab fast tracked for IPF . Discussion : FibroGen's anti-CTGF antibody pamrevlumab indicated in idiopathic pulmonary fibrosis ((IPF)) is now under Fast Track review of the FDA. The new status allows a rolling review of the market… read more...
Your Daily Pharma Scoop: FibroGen Fast Tracked, Dr. Reddy's Entry, Bristol-Myers Succeeds
via: SeekingAlpha at 2018-09-15 00:16:06:000
Stocks in News: [[FGEN]], [[RDY]] FibroGen's pamrevlumab fast tracked for IPF . Discussion : FibroGen's anti-CTGF antibody pamrevlumab indicated in idiopathic pulmonary fibrosis ((IPF)) is now under Fast Track review of the FDA. The new status allows a rolling review of the market… read more...
Your Daily Pharma Scoop: FibroGen Fast Tracked, Dr. Reddy's Entry, Bristol-Myers Succeeds
via: SeekingAlpha at 2018-09-15 00:16:06:000
Stocks in News: [[FGEN]], [[RDY]] FibroGen's pamrevlumab fast tracked for IPF . Discussion : FibroGen's anti-CTGF antibody pamrevlumab indicated in idiopathic pulmonary fibrosis ((IPF)) is now under Fast Track review of the FDA. The new status allows a rolling review of the market… read more...
Nostrum Labs hikes price of mature antibiotic 400%
via: SeekingAlpha at 2018-09-12 11:50:15:000
In a move that would make Martin Shkreli proud, privately held Nostrum Laboratories has increased the price of antibiotic nitrofurantoin, on the market since 1953 to treat bladder infections, 400%. A bottle of the pills now costs $2,393, up from ~$475. More news on: Amneal Pharmaceutical… read more...
Nostrum Labs hikes price of mature antibiotic 400%
via: SeekingAlpha at 2018-09-12 11:50:15:000
In a move that would make Martin Shkreli proud, privately held Nostrum Laboratories has increased the price of antibiotic nitrofurantoin, on the market since 1953 to treat bladder infections, 400%. A bottle of the pills now costs $2,393, up from ~$475. More news on: Amneal Pharmaceutical… read more...
Nostrum Labs hikes price of mature antibiotic 400%
via: SeekingAlpha at 2018-09-12 11:50:15:000
In a move that would make Martin Shkreli proud, privately held Nostrum Laboratories has increased the price of antibiotic nitrofurantoin, on the market since 1953 to treat bladder infections, 400%. A bottle of the pills now costs $2,393, up from ~$475. More news on: Amneal Pharmaceutical… read more...
The FDA approves Amneal Pharmaceuticals' chlorpromazine hydrochloride tablets and generic version of methylergonovine maleate tablets
via: SeekingAlpha at 2018-09-12 08:09:12:000
The FDA has approved Amneal Pharmaceuticals' (NYSE: AMRX ) ANDA for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg and 200 mg and has immediately initiated commercialization activities. More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks news, Read mo… read more...
The FDA approves Amneal Pharmaceuticals' chlorpromazine hydrochloride tablets and generic version of methylergonovine maleate tablets
via: SeekingAlpha at 2018-09-12 08:09:12:000
The FDA has approved Amneal Pharmaceuticals' (NYSE: AMRX ) ANDA for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg and 200 mg and has immediately initiated commercialization activities. More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks news, Read mo… read more...
The FDA approves Amneal Pharmaceuticals' chlorpromazine hydrochloride tablets and generic version of methylergonovine maleate tablets
via: SeekingAlpha at 2018-09-12 08:09:12:000
The FDA has approved Amneal Pharmaceuticals' (NYSE: AMRX ) ANDA for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg and 200 mg and has immediately initiated commercialization activities. More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks news, Read mo… read more...
Amneal Announces FDA Approval and Launch of Generic Chlorpromazine Hydrochloride Tablets USP and Approval of Methylergonovine Maleate Tablets USP
via: PR Newswire at 2018-09-12 07:30:00:000
BRIDGEWATER, N.J. , Sept. 12, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced it has received U.S. Food and Drug Administration (FDA) approval on its Abbreviated New Drug Application (ANDA) for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, … read more...
Amneal Announces FDA Approval and Launch of Generic Chlorpromazine Hydrochloride Tablets USP and Approval of Methylergonovine Maleate Tablets USP
via: PR Newswire at 2018-09-12 07:30:00:000
BRIDGEWATER, N.J. , Sept. 12, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced it has received U.S. Food and Drug Administration (FDA) approval on its Abbreviated New Drug Application (ANDA) for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, … read more...
Amneal Announces FDA Approval and Launch of Generic Chlorpromazine Hydrochloride Tablets USP and Approval of Methylergonovine Maleate Tablets USP
via: PR Newswire at 2018-09-12 07:30:00:000
BRIDGEWATER, N.J. , Sept. 12, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced it has received U.S. Food and Drug Administration (FDA) approval on its Abbreviated New Drug Application (ANDA) for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, … read more...
Amneal to Present at Upcoming Investor Conferences
via: PR Newswire at 2018-08-31 08:00:00:000
BRIDGEWATER, N.J. , Aug. 31, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it plans to participate at the following upcoming investor conferences. Wells Fargo 2018 Healthcare Conference at 9:10 a.m. ET on September 6, 2018 in Boston, MA… read more...
Amneal to Present at Upcoming Investor Conferences
via: PR Newswire at 2018-08-31 08:00:00:000
BRIDGEWATER, N.J. , Aug. 31, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it plans to participate at the following upcoming investor conferences. Wells Fargo 2018 Healthcare Conference at 9:10 a.m. ET on September 6, 2018 in Boston, MA… read more...
Amneal to Present at Upcoming Investor Conferences
via: PR Newswire at 2018-08-31 08:00:00:000
BRIDGEWATER, N.J. , Aug. 31, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it plans to participate at the following upcoming investor conferences. Wells Fargo 2018 Healthcare Conference at 9:10 a.m. ET on September 6, 2018 in Boston, MA… read more...
Amneal to Present at Upcoming Investor Conferences
via: PR Newswire at 2018-08-31 08:00:00:000
BRIDGEWATER, N.J. , Aug. 31, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it plans to participate at the following upcoming investor conferences. Wells Fargo 2018 Healthcare Conference at 9:10 a.m. ET on September 6, 2018 in Boston, MA… read more...
Amneal to Present at Upcoming Investor Conferences
via: PR Newswire at 2018-08-31 08:00:00:000
BRIDGEWATER, N.J. , Aug. 31, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it plans to participate at the following upcoming investor conferences. Wells Fargo 2018 Healthcare Conference at 9:10 a.m. ET on September 6, 2018 in Boston, MA… read more...
Amneal to Present at Upcoming Investor Conferences
via: PR Newswire at 2018-08-31 08:00:00:000
BRIDGEWATER, N.J. , Aug. 31, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it plans to participate at the following upcoming investor conferences. Wells Fargo 2018 Healthcare Conference at 9:10 a.m. ET on September 6, 2018 in Boston, MA… read more...
Amneal inks deal with American Regent on Makena and progress on its business plan with additional ANDA approvals and launches
via: SeekingAlpha at 2018-08-31 07:42:58:000
Amneal Pharmaceuticals (NYSE: AMRX ) announces a 5-year supply and distribution agreement with American Regent for the only preservative-free generic alternative to Makena (hydroxyprogesterone caproate injection, USP, 250mg/mL). The injectable is used to reduce the risk of preterm birth in… read more...
Amneal inks deal with American Regent on Makena and progress on its business plan with additional ANDA approvals and launches
via: SeekingAlpha at 2018-08-31 07:42:58:000
Amneal Pharmaceuticals (NYSE: AMRX ) announces a 5-year supply and distribution agreement with American Regent for the only preservative-free generic alternative to Makena (hydroxyprogesterone caproate injection, USP, 250mg/mL). The injectable is used to reduce the risk of preterm birth in… read more...
Amneal inks deal with American Regent on Makena and progress on its business plan with additional ANDA approvals and launches
via: SeekingAlpha at 2018-08-31 07:42:58:000
Amneal Pharmaceuticals (NYSE: AMRX ) announces a 5-year supply and distribution agreement with American Regent for the only preservative-free generic alternative to Makena (hydroxyprogesterone caproate injection, USP, 250mg/mL). The injectable is used to reduce the risk of preterm birth in… read more...
Amneal inks deal with American Regent on Makena and progress on its business plan with additional ANDA approvals and launches
via: SeekingAlpha at 2018-08-31 07:42:58:000
Amneal Pharmaceuticals (NYSE: AMRX ) announces a 5-year supply and distribution agreement with American Regent for the only preservative-free generic alternative to Makena (hydroxyprogesterone caproate injection, USP, 250mg/mL). The injectable is used to reduce the risk of preterm birth in… read more...
Amneal inks deal with American Regent on Makena and progress on its business plan with additional ANDA approvals and launches
via: SeekingAlpha at 2018-08-31 07:42:58:000
Amneal Pharmaceuticals (NYSE: AMRX ) announces a 5-year supply and distribution agreement with American Regent for the only preservative-free generic alternative to Makena (hydroxyprogesterone caproate injection, USP, 250mg/mL). The injectable is used to reduce the risk of preterm birth in… read more...
Amneal inks deal with American Regent on Makena and progress on its business plan with additional ANDA approvals and launches
via: SeekingAlpha at 2018-08-31 07:42:58:000
Amneal Pharmaceuticals (NYSE: AMRX ) announces a 5-year supply and distribution agreement with American Regent for the only preservative-free generic alternative to Makena (hydroxyprogesterone caproate injection, USP, 250mg/mL). The injectable is used to reduce the risk of preterm birth in… read more...
Amneal Announces Partnership with American Regent on Generic Makena® and Progress on its Business Plan with Additional ANDA Approvals and Launches
via: PR Newswire at 2018-08-31 07:30:00:000
BRIDGEWATER, N.J. , Aug. 31, 2018 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced a 5-year supply and distribution agreement with American Regent for the only preservative-free generic alternative to Makena (hydroxy… read more...
Amneal Announces Partnership with American Regent on Generic Makena® and Progress on its Business Plan with Additional ANDA Approvals and Launches
via: PR Newswire at 2018-08-31 07:30:00:000
BRIDGEWATER, N.J. , Aug. 31, 2018 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced a 5-year supply and distribution agreement with American Regent for the only preservative-free generic alternative to Makena (hydroxy… read more...
Amneal Announces Partnership with American Regent on Generic Makena® and Progress on its Business Plan with Additional ANDA Approvals and Launches
via: PR Newswire at 2018-08-31 07:30:00:000
BRIDGEWATER, N.J. , Aug. 31, 2018 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced a 5-year supply and distribution agreement with American Regent for the only preservative-free generic alternative to Makena (hydroxy… read more...
Amneal Announces Partnership with American Regent on Generic Makena® and Progress on its Business Plan with Additional ANDA Approvals and Launches
via: PR Newswire at 2018-08-31 07:30:00:000
BRIDGEWATER, N.J. , Aug. 31, 2018 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced a 5-year supply and distribution agreement with American Regent for the only preservative-free generic alternative to Makena (hydroxy… read more...
Amneal Announces Partnership with American Regent on Generic Makena® and Progress on its Business Plan with Additional ANDA Approvals and Launches
via: PR Newswire at 2018-08-31 07:30:00:000
BRIDGEWATER, N.J. , Aug. 31, 2018 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced a 5-year supply and distribution agreement with American Regent for the only preservative-free generic alternative to Makena (hydroxy… read more...
Amneal Announces Partnership with American Regent on Generic Makena® and Progress on its Business Plan with Additional ANDA Approvals and Launches
via: PR Newswire at 2018-08-31 07:30:00:000
BRIDGEWATER, N.J. , Aug. 31, 2018 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced a 5-year supply and distribution agreement with American Regent for the only preservative-free generic alternative to Makena (hydroxy… read more...
Amneal Pharma inks 10-year distribution deal with Jerome Stevens for Levothyroxine
via: SeekingAlpha at 2018-08-20 08:01:38:000
Privately held Jerome Stevens Pharmaceuticals enters into a 10-year distribution agreement with Amneal Pharmaceuticals (NYSE: AMRX ) for Levothyroxine sodium tablets beginning on March 22, 2019, transitioning from Lannett Company. More news on: Amneal Pharmaceuticals, Inc., Healthcare st… read more...
Amneal Pharma inks 10-year distribution deal with Jerome Stevens for Levothyroxine
via: SeekingAlpha at 2018-08-20 08:01:38:000
Privately held Jerome Stevens Pharmaceuticals enters into a 10-year distribution agreement with Amneal Pharmaceuticals (NYSE: AMRX ) for Levothyroxine sodium tablets beginning on March 22, 2019, transitioning from Lannett Company. More news on: Amneal Pharmaceuticals, Inc., Healthcare st… read more...
Amneal Pharma inks 10-year distribution deal with Jerome Stevens for Levothyroxine
via: SeekingAlpha at 2018-08-20 08:01:38:000
Privately held Jerome Stevens Pharmaceuticals enters into a 10-year distribution agreement with Amneal Pharmaceuticals (NYSE: AMRX ) for Levothyroxine sodium tablets beginning on March 22, 2019, transitioning from Lannett Company. More news on: Amneal Pharmaceuticals, Inc., Healthcare st… read more...
Amneal Announces 10-Year Licensing and Supply Agreement with Jerome Stevens Pharmaceuticals, Inc. for Levothyroxine
via: PR Newswire at 2018-08-20 07:30:00:000
BRIDGEWATER, N.J. , Aug. 20, 2018 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced a 10-year license and supply agreement for Levothyroxine sodium tablets with Jerome Stevens Pharmaceuticals, Inc. (JSP), a New York -based… read more...
Amneal Announces 10-Year Licensing and Supply Agreement with Jerome Stevens Pharmaceuticals, Inc. for Levothyroxine
via: PR Newswire at 2018-08-20 07:30:00:000
BRIDGEWATER, N.J. , Aug. 20, 2018 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced a 10-year license and supply agreement for Levothyroxine sodium tablets with Jerome Stevens Pharmaceuticals, Inc. (JSP), a New York -based… read more...
Amneal Announces 10-Year Licensing and Supply Agreement with Jerome Stevens Pharmaceuticals, Inc. for Levothyroxine
via: PR Newswire at 2018-08-20 07:30:00:000
BRIDGEWATER, N.J. , Aug. 20, 2018 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced a 10-year license and supply agreement for Levothyroxine sodium tablets with Jerome Stevens Pharmaceuticals, Inc. (JSP), a New York -based… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-08-13 07:45:32:000
Constellation Pharmaceuticals (NASDAQ: CNST ) initiated with Overweight rating and $17 (73% upside) price target at JPMorgan. More news on: Constellation Pharmaceuticals, Mylan Inc, Endo International plc, Healthcare stocks news, Stocks on the move, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-08-13 07:45:32:000
Constellation Pharmaceuticals (NASDAQ: CNST ) initiated with Overweight rating and $17 (73% upside) price target at JPMorgan. More news on: Constellation Pharmaceuticals, Mylan Inc, Endo International plc, Healthcare stocks news, Stocks on the move, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-08-13 07:45:32:000
Constellation Pharmaceuticals (NASDAQ: CNST ) initiated with Overweight rating and $17 (73% upside) price target at JPMorgan. More news on: Constellation Pharmaceuticals, Mylan Inc, Endo International plc, Healthcare stocks news, Stocks on the move, Read more … read more...
Amneal Pharmaceuticals, Inc. 2018 Q2 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-08-11 00:33:59:000
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2018 Q2 earnings Read more … read more...
Amneal Pharmaceuticals, Inc. 2018 Q2 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-08-11 00:33:59:000
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2018 Q2 earnings Read more … read more...
Amneal Pharmaceuticals, Inc. (AMRX) CEO Rob Stewart on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-09 14:36:49:000
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2018 Earnings Conference Call August 9, 2018 8:30 AM ET Executives Mark Donohue - Investor Relations Rob Stewart - President and Chief Executive Officer Bryan Reasons - Chief Financial Officer Paul Bisaro - Executive Chairman Analysts … read more...
Amneal Pharmaceuticals, Inc. (AMRX) CEO Rob Stewart on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-09 14:36:49:000
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2018 Earnings Conference Call August 9, 2018 8:30 AM ET Executives Mark Donohue - Investor Relations Rob Stewart - President and Chief Executive Officer Bryan Reasons - Chief Financial Officer Paul Bisaro - Executive Chairman Analysts … read more...
Amneal Pharmaceuticals beats by $0.02, beats on revenue
via: SeekingAlpha at 2018-08-09 07:07:14:000
Amneal Pharmaceuticals (NYSE: AMRX ): Q2 EPS of $0.24 beats by $0.02 . More news on: Amneal Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Amneal Pharmaceuticals beats by $0.02, beats on revenue
via: SeekingAlpha at 2018-08-09 07:07:14:000
Amneal Pharmaceuticals (NYSE: AMRX ): Q2 EPS of $0.24 beats by $0.02 . More news on: Amneal Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Amneal Announces Solid Second Quarter 2018 Financial Results
via: PR Newswire at 2018-08-09 07:00:00:000
BRIDGEWATER, N.J. , Aug. 9, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the quarter ended June 30, 2018 . "We delivered solid sequential growth across our Generics and Specialty Pharma businesses on a combined adjust… read more...
Amneal Announces Solid Second Quarter 2018 Financial Results
via: PR Newswire at 2018-08-09 07:00:00:000
BRIDGEWATER, N.J. , Aug. 9, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the "Company") announced its results today for the quarter ended June 30, 2018 . "We delivered solid sequential growth across our Generics and Specialty Pharma businesses on a combined adjust… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-07-23 08:19:15:000
Centene (NYSE: CNC ) initiated with Overweight rating and $158 (17% upside) price target at Barclays. More news on: Centene Corporation, Molina Healthcare, Inc., WellCare Health Plans, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-07-23 08:19:15:000
Centene (NYSE: CNC ) initiated with Overweight rating and $158 (17% upside) price target at Barclays. More news on: Centene Corporation, Molina Healthcare, Inc., WellCare Health Plans, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-07-23 08:19:15:000
Centene (NYSE: CNC ) initiated with Overweight rating and $158 (17% upside) price target at Barclays. More news on: Centene Corporation, Molina Healthcare, Inc., WellCare Health Plans, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Amneal Announces FDA Approval and Launch of Generic Potassium Chloride Oral Solution
via: PR Newswire at 2018-07-23 07:30:00:000
BRIDGEWATER, N.J. , July 23, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced it has received U.S. Food and Drug Administration (FDA) approval on its Abbreviated New Drug Application for a generic version of Potas… read more...
Amneal Announces FDA Approval and Launch of Generic Potassium Chloride Oral Solution
via: PR Newswire at 2018-07-23 07:30:00:000
BRIDGEWATER, N.J. , July 23, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced it has received U.S. Food and Drug Administration (FDA) approval on its Abbreviated New Drug Application for a generic version of Potas… read more...
Amneal Announces FDA Approval and Launch of Generic Potassium Chloride Oral Solution
via: PR Newswire at 2018-07-23 07:30:00:000
BRIDGEWATER, N.J. , July 23, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced it has received U.S. Food and Drug Administration (FDA) approval on its Abbreviated New Drug Application for a generic version of Potas… read more...
Amneal to Report Second Quarter 2018 Results on August 9, 2018
via: PR Newswire at 2018-06-29 08:15:00:000
BRIDGEWATER, N.J. , June 29, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2018 financial results on Thursday, August 9, 2018 , prior to the open of the U.S. financial markets. The Company will host … read more...
Amneal to Report Second Quarter 2018 Results on August 9, 2018
via: PR Newswire at 2018-06-29 08:15:00:000
BRIDGEWATER, N.J. , June 29, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2018 financial results on Thursday, August 9, 2018 , prior to the open of the U.S. financial markets. The Company will host … read more...
Amneal to Report Second Quarter 2018 Results on August 9, 2018
via: PR Newswire at 2018-06-29 08:15:00:000
BRIDGEWATER, N.J. , June 29, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2018 financial results on Thursday, August 9, 2018 , prior to the open of the U.S. financial markets. The Company will host … read more...
Amneal to Report Second Quarter 2018 Results on August 9, 2018
via: PR Newswire at 2018-06-29 08:15:00:000
BRIDGEWATER, N.J. , June 29, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2018 financial results on Thursday, August 9, 2018 , prior to the open of the U.S. financial markets. The Company will host … read more...
Amneal to Report Second Quarter 2018 Results on August 9, 2018
via: PR Newswire at 2018-06-29 08:15:00:000
BRIDGEWATER, N.J. , June 29, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2018 financial results on Thursday, August 9, 2018 , prior to the open of the U.S. financial markets. The Company will host … read more...
Amneal Announces Favorable Ruling Regarding Patent Validity for Zomig® (zolmitriptan) Nasal Spray
via: PR Newswire at 2018-06-29 07:30:00:000
BRIDGEWATER, N.J. , June 29, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that a panel of three Circuit Judges of the U.S. Court of Appeals for the Federal Circuit has affirmed the March 30, 2017 ruling of JudgeRichard G…. read more...
Amneal Announces Favorable Ruling Regarding Patent Validity for Zomig® (zolmitriptan) Nasal Spray
via: PR Newswire at 2018-06-29 07:30:00:000
BRIDGEWATER, N.J. , June 29, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that a panel of three Circuit Judges of the U.S. Court of Appeals for the Federal Circuit has affirmed the March 30, 2017 ruling of JudgeRichard G…. read more...
Amneal Announces Favorable Ruling Regarding Patent Validity for Zomig® (zolmitriptan) Nasal Spray
via: PR Newswire at 2018-06-29 07:30:00:000
BRIDGEWATER, N.J. , June 29, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that a panel of three Circuit Judges of the U.S. Court of Appeals for the Federal Circuit has affirmed the March 30, 2017 ruling of JudgeRichard G…. read more...
Amneal Announces Favorable Ruling Regarding Patent Validity for Zomig® (zolmitriptan) Nasal Spray
via: PR Newswire at 2018-06-29 07:30:00:000
BRIDGEWATER, N.J. , June 29, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that a panel of three Circuit Judges of the U.S. Court of Appeals for the Federal Circuit has affirmed the March 30, 2017 ruling of JudgeRichard G…. read more...
Amneal Announces Favorable Ruling Regarding Patent Validity for Zomig® (zolmitriptan) Nasal Spray
via: PR Newswire at 2018-06-29 07:30:00:000
BRIDGEWATER, N.J. , June 29, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that a panel of three Circuit Judges of the U.S. Court of Appeals for the Federal Circuit has affirmed the March 30, 2017 ruling of JudgeRichard G…. read more...
Amneal Announces Patent Litigation Settlement Agreement with Actavis Concerning Rytary®
via: PR Newswire at 2018-06-20 06:55:00:000
BRIDGEWATER, N.J. , June 20, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced that it has entered into a settlement agreement with Actavis Laboratories FL, Inc. and Actavis Pharma Inc. (collectively, "Actavis")… read more...
Amneal Announces Patent Litigation Settlement Agreement with Actavis Concerning Rytary®
via: PR Newswire at 2018-06-20 06:55:00:000
BRIDGEWATER, N.J. , June 20, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced that it has entered into a settlement agreement with Actavis Laboratories FL, Inc. and Actavis Pharma Inc. (collectively, "Actavis")… read more...
Amneal to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
via: PR Newswire at 2018-06-06 07:50:00:000
BRIDGEWATER, N.J. , June 6, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that Rob Stewart , President and Chief Executive Officer, and Bryan Reasons , Senior Vice President and Chief Financial Officer, will present at the Goldman Sachs … read more...
Amneal to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
via: PR Newswire at 2018-06-06 07:50:00:000
BRIDGEWATER, N.J. , June 6, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that Rob Stewart , President and Chief Executive Officer, and Bryan Reasons , Senior Vice President and Chief Financial Officer, will present at the Goldman Sachs … read more...
Amneal to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
via: PR Newswire at 2018-06-06 07:50:00:000
BRIDGEWATER, N.J. , June 6, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that Rob Stewart , President and Chief Executive Officer, and Bryan Reasons , Senior Vice President and Chief Financial Officer, will present at the Goldman Sachs … read more...
Impax Laboratories, LLC Announces Results of Tender Offer for 2.00% Convertible Senior Notes Due 2022
via: PR Newswire at 2018-06-05 16:15:00:000
HAYWARD, Calif. , June 5, 2018 /PRNewswire/ -- Impax Laboratories, LLC ("Impax" or the "Company"), a wholly-owned subsidiary of Amneal Pharmaceuticals, Inc. (NYSE: AMRX), announced today the final results of its previously announced cash tender offer (the "Offer") to repurchase any and … read more...
Amneal Announces FDA Approval of Cyclophosphamide for Injection USP, Generic to Cytoxan®
via: PR Newswire at 2018-05-30 07:15:00:000
BRIDGEWATER, N.J. , May 30, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced it has received U.S. Food and Drug Administration (FDA) approval on its Abbreviated New Drug Application (ANDA) for Cyclophosphamide … read more...
Amneal Announces FDA Approval of Cyclophosphamide for Injection USP, Generic to Cytoxan®
via: PR Newswire at 2018-05-30 07:15:00:000
BRIDGEWATER, N.J. , May 30, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced it has received U.S. Food and Drug Administration (FDA) approval on its Abbreviated New Drug Application (ANDA) for Cyclophosphamide … read more...
Amneal Announces FDA Approval of Cyclophosphamide for Injection USP, Generic to Cytoxan®
via: PR Newswire at 2018-05-30 07:15:00:000
BRIDGEWATER, N.J. , May 30, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced it has received U.S. Food and Drug Administration (FDA) approval on its Abbreviated New Drug Application (ANDA) for Cyclophosphamide … read more...
mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
via: PR Newswire at 2018-05-23 07:29:00:000
MADRID , May 23, 2018 /PRNewswire/ -- mAbxience, a company specialized in the research, development, manufacturing and global commercialization of monoclonal antibody biosimilars, part of the Insud Pharma Group and Amneal Pharmaceuticals, Inc. (NYSE: AMRX), an integrated specialty pharm… read more...
mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
via: PR Newswire at 2018-05-23 07:29:00:000
MADRID , May 23, 2018 /PRNewswire/ -- mAbxience, a company specialized in the research, development, manufacturing and global commercialization of monoclonal antibody biosimilars, part of the Insud Pharma Group and Amneal Pharmaceuticals, Inc. (NYSE: AMRX), an integrated specialty pharm… read more...
mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
via: PR Newswire at 2018-05-23 07:29:00:000
MADRID , May 23, 2018 /PRNewswire/ -- mAbxience, a company specialized in the research, development, manufacturing and global commercialization of monoclonal antibody biosimilars, part of the Insud Pharma Group and Amneal Pharmaceuticals, Inc. (NYSE: AMRX), an integrated specialty pharm… read more...
Amneal Pharmaceuticals (AMRX) Presents At 2018 UBS Global Healthcare Conference - Slideshow
via: SeekingAlpha at 2018-05-22 13:29:52:000
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-05-18 08:57:57:000
Aimmune Therapeutics (NASDAQ: AIMT ) initiated with Overweight rating and $60 (100% upside) price target at Piper Jaffray. More news on: Aimmune Therapeutics, Alpine Immune Sciences, Inc., Amneal Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Amneal Pharmaceuticals Celebrates Combination by Ringing Opening Bell at New York Stock Exchange
via: PR Newswire at 2018-05-18 06:45:00:000
BRIDGEWATER, N.J. , May 18, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), an integrated specialty pharmaceutical company, today announced that its founders along with members of management will ring the opening bell at the New York Stock Exchange this morni… read more...
Amneal Announces FDA Approval and Launch of Generic Welchol® (Colesevelam HCl) Tablets, 625 mg
via: PR Newswire at 2018-05-17 09:15:00:000
BRIDGEWATER, N.J. , May 17, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced it has received final U.S. Food and Drug Administration (FDA) approval on its Abbreviated New Drug Application for a generic version of … read more...
Amneal Introduces First Generic for Mephyton® (Phytonadione) Tablets, 5mg
via: PR Newswire at 2018-05-15 08:30:00:000
BRIDGEWATER, N.J. , May 15, 2018 /PRNewswire/ -- Amneal Pharmaceuticals , Inc. (NYSE: AMRX) has launched Phytonadione Tablets, USP, 5 mg, the first AB-rated therapeutic equivalent for Mephyton . The product is available in 100-ct bottles and is now shipping to whol… read more...
Amneal Introduces First Generic for Mephyton® (Phytonadione) Tablets, 5mg
via: PR Newswire at 2018-05-15 08:30:00:000
BRIDGEWATER, N.J. , May 15, 2018 /PRNewswire/ -- Amneal Pharmaceuticals , Inc. (NYSE: AMRX) has launched Phytonadione Tablets, USP, 5 mg, the first AB-rated therapeutic equivalent for Mephyton . The product is available in 100-ct bottles and is now shipping to whol… read more...
Amneal Introduces First Generic for Mephyton® (Phytonadione) Tablets, 5mg
via: PR Newswire at 2018-05-15 08:30:00:000
BRIDGEWATER, N.J. , May 15, 2018 /PRNewswire/ -- Amneal Pharmaceuticals , Inc. (NYSE: AMRX) has launched Phytonadione Tablets, USP, 5 mg, the first AB-rated therapeutic equivalent for Mephyton . The product is available in 100-ct bottles and is now shipping to whol… read more...
Amneal Introduces First Generic for Mephyton® (Phytonadione) Tablets, 5mg
via: PR Newswire at 2018-05-15 08:30:00:000
BRIDGEWATER, N.J. , May 15, 2018 /PRNewswire/ -- Amneal Pharmaceuticals , Inc. (NYSE: AMRX) has launched Phytonadione Tablets, USP, 5 mg, the first AB-rated therapeutic equivalent for Mephyton . The product is available in 100-ct bottles and is now shipping to whol… read more...
Amneal to Present at the UBS Global Healthcare Conference
via: PR Newswire at 2018-05-14 07:55:00:000
BRIDGEWATER, N.J. , May 14, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that Rob Stewart , President and Chief Executive Officer of Amneal, will present at the UBS Global Healthcare Conference on Monday, May 21, 2018 at 8:30 a.m. Eastern Tim… read more...
Amneal Pharmaceuticals reports Q1 results
via: SeekingAlpha at 2018-05-11 18:03:09:000
Amneal Pharmaceuticals (NYSE: AMRX ): Q1 EPS of -$1.81 Revenue of $142.35M (-22.8% Y/Y) Press Release More news on: Amneal Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , read more...
Amneal announces actions to streamline operations and capture cost synergies
via: SeekingAlpha at 2018-05-11 08:00:03:000
Amneal Pharmaceuticals (NYSE: AMRX ) announces actions to streamline operations following analysis of its current and future product portfolios, plant capacities, and cost structure as a result of the recent business combination with Impax Laboratories. As a result, the Company will close … read more...
Amneal Announces Actions to Streamline Operations and Capture Cost Synergies
via: PR Newswire at 2018-05-11 07:30:00:000
BRIDGEWATER, N.J. , May 11, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced actions to streamline operations following a comprehensive analysis of its current and future product portfolios, plant capacities, overlapping capabilities and cost structure as … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|